This is a prospective, randomized, multi-center study in which 300 evaluable subjects will be randomized 1:1 to receive Active or Delayed therapy with Moventis PNS. Subjects in the Delayed group will start with therapy at 3-month visit follow up.
This is a prospective, randomized, controlled, multi-center study in which 300 evaluable subjects will receive Moventis PNS. Target subjects will have idiopathic hip pain. Subjects will be randomized into either a delayed or immediate continuation group. Devices will be activated post-op in accordance to the randomization assignment. Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study. Implanted subjects will be educated on the use of the transmitter. Programming changes can be done as needed during this time period to maximize clinical response according to pre-programmed settings. Subjects randomized to the Delayed group will begin 2-hour stimulation/day at the 3-Month visit. The primary endpoint is to demonstrate clinically significant improvements in the pain of patients in the active group compared to the subjects in the delayed group. The primary endpoint is defined as \>50% pain relief at 3-months as measured by the Visual Analog Scale (VAS) without increase in baseline pain medications. Improvement will be assessed in relation to the clinical outcome measures of pain, with a target of \>50% pain relief.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
300
Moventis PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
Rate of Change in Pain Relief: >50% pain relief as measured by Visual Analog Scale
Improvement pain defined as a \>50% pain relief as measured by VAS without increase in baseline medications. To demonstrate clinically significant improvements in the pain of subjects in the active group compared to the subjects in the delayed group.
Time frame: 3 Months
Adverse Events
Device- and procedure-related Adverse Events (AE) rate at 3-months.
Time frame: 3 Months
Change in Hip Pain: measured by Hip Pain Questionnaire
Current hip pain will be accessed and the history of hip pain will be recorded.
Time frame: 3, 6, 9, 12, 24, 36-months
Rate of Change in Pain Relief: >50% pain relief as measured by Visual Analog Scale
Improvement pain defined as a \>50% pain relief as measured by VAS without increase in baseline medications. To demonstrate clinically significant improvements in the pain of subjects in the active group compared to the subjects in the delayed group.
Time frame: 6, 9, 12, 24, 36-Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.